ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number - Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-4,016,043	04-5-1977	Schuurs et al.	
	2	US-4,172,124	10-23-1979	Koprowski et al.	
	3	US-4,474,893	10-02-1984	Reading	
	4	US-4,971,903	11-20-1990	Hyman	
	5	US-5,331,573	07-19-1994	Balaji et al.	
	6	US-5,579,250	11-26-1996	Balaji et al.	
	~~7~~	~~US-2001/018465~~	~~11-24-2000~~	~~McGill University~~	
	8	US-6,331,614	12-18-2001	Wong et al.	
	9	US-2003/0157525	11-21-2003	Mintier et al.	
	10	US-2004/0096886	05-20-2004	Rouleau et al.	
	11	US 2004-0110706	06-10-2004	Wallace et al.	
	12	US-2004/0214195	10-28-2004	Rouleau et al.	
	13	U8-2004/0229257	11-18-2004	Petrou et al.	
	14	US 2005-0074764	04-07-2005	Mulley et al.	
	15	US-2006-0089306	04-27-2006	Wallace et al.	
	16	US-7,078,515	07-18-2006	Wallace et al.	
	17	US-2006-0252121	11-09-2006	Wallace et al.	
	18	US-7,282,336	10-16-2007	Wallace et al.	
	19	US-2010/0088778	04-08-2010	Mulley et al.	
	20	US-7,709,225	05-24-2010	Wallace et al.	
	21	US-7,723,027	05-25-2010	Petrou et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] - Number[4] - Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	22	WO84/03564	09-13-1984	Commonwealth Serum Laboratories Commission		
	23	AU656247	06-28-1996	Women's and Children's Hospital		
	24	WO97/02048	01-23-1997	Millennium Pharmaceuticals, Inc.		
	25	WO 2001/38564	05-31-2001	McGill University, CA		
	26	WO01/88125	11-22-2001	Bionomics Limited		
	27	WO01/98486	12-27-2001	Bionomics Limited		
	28	WO 2002/006521	01-24-2002	Bionomics Limited		
	29	WO 2002/050096	06-27-2002	Bionomics Limited		
	30	WO03/008574	01-30-2003	Mulley		
	31	WO 2004/085674	10-07-2004	Bionomics Limited		
	32	WO 2005/014863	02-17-2005	Bionomics Limited		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	33	Abstracts of Decisions. Decision of a Delegate of the Commissioner of Patents corresponding to an Australian Patent Application No. 18465/01 issued January 29, 2007.	
	34	Alekov et al., "A sodium channel mutation causing epilepsy in man exhibits subtle defects in fast inactivation and activation *in vitro*," Journal of Physiology, Vol. 529, No. 3, pgs. 533-539 (2000).	
	35	Andermann, "Multifactorial Inheritance of Generalized and Focal Epilepsy," Genetic Basis of the Epilepsies, pgs. 355-374 (1982).	
	36	Annegers, "The Epidemiology of Epilepsy," The Treatment of Epilepsy: Principles and Practice, Chpt. 11, pgs. 165-172 (1996).	
	37	Baulac et al., "A Second Locus for Familial Generalized Epilepsy with Febrile Seizures Plus Maps to Chromosome 2q21-q33," Am. J. Hum. Genet., Vol. 65, pgs. 1078-1085 (1999).	
	38	Bell and Lathrop, "Multiple loci for multiple sclerosis," Nature Genetics, Vol. 13, pgs. 377-378 (August 1996).	
	39	Bendahhou et al., "Activation and Inactivation of the Voltage-Gated Sodium Channel: Role of Segment S5 Revealed by a Novel Hyperkalaemic Periodic Paralysis Mutation," J. Neurosci., Vol. 19, pgs. 4762-4771 (1999).	
	40	Berkovic et al., "Concepts of absence epilepsies: Discrete syndromes or biological continuum?" Neurology, Vol. 37, No. 6, pgs. 993-1000 (June 1987).	
	41	Berkovic et al., "Familial Epilepsies in Israel: Clinical Syndromes and Modes of Inheritance," Neurology, Vol. 54, Suppl. 3, A356, No. P05.063 (April 2000).	
	42	Berkovic et al., "The epilepsies: specific syndromes or a neurobiological continuum?" Epileptic Seizures and Syndromes, Chpt. 5, pgs. 25-37 (1994).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	43	Bertrand et al., "Properties of neuronal nicotinic acetylcholine receptor mutants from humans suffering from autosomal dominant nocturnal frontal lobe epilepsy," British J. of Pharmacology, Vol. 124, pgs. 1-10 (1998).	
	44	Bievert et al., "A Potassium Channel Mutation in Neonatal Human Epilepsy," Science, Vol. 279, pgs. 403-406 (January 16, 1998).	
	45	Bourgeois, "Chronic Management of Seizures in the Syndromes of Idiopathic Generalized Epilepsy," Epilepsia, 44 (Suppl. 2), pgs. 27-32 (2003).	
	46	Cannon, "Sodium Channel Gating: No Margin for Error," Neuron, Vol. 34, pgs. 853-858 (June 13, 2002).	
	47	Cavazzuti et al., "Longitudinal Study of Epileptiform EEG Patterns in Normal Children," Epilepsia, Vol. 21, pgs. 43-55 (1980).	
	48	Charlier et al., "A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family," Nature Genetics, Vol. 18, pgs. 53-55 (January 1998).	
	49	Chou et al., "The lack of association between febrile convulsions and polymorphisms in SCNIA," Epilepsy Research, Vol. 54, pgs. 53-57 (2003).	
	50	Claes et al., "De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy," American Journal of Human Genetics, Vol. 68, pgs. 1327-1332 (2001).	
	51	Collins, "Positional cloning moves from perditional to traditional," Nature Genetics, Vol. 9, pgs. 347-349 (April 1995).	
	52	Commission on Classification and Terminology of the International League Against Epilepsy, "Proposal for Revised Classification of Epilepsies and Epileptic Syndromes," Epilepsia, Vol. 30, No. 4, pgs. 389-399 (1989).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	53	Communication pursuant to Rule 46(1) EPC corresponding to European Application No. 04718885.9-2402 PCT/AU2004000295 dated July 14, 2006.	
	54	DATABASE UniProt, "Sodium channel protein type I alpha subunit," XP002313393, retrieved from EBI accession no., UNIPROT: CIN1_HUMAN, Database accession no. P35498. (ABSTRACT)	
	55	DePalma, A., "Capturing Proteins Using Antibody Arrays," from Genomics and Proteomics; available online from author at www.adeplama.com, pgs. 1-5.	
	56	Doose and Baier, "Genetic Aspects of Childhood Epilepsy," Cleveland Clinic Journal of Medicine, Vol. 56, Suppl. Part 1, S101-S110 (1989).	
	57	Doose and Baier, "Genetic Factors in Epilepsies with Primarily Generalized Minor Seizures," Neuropediatrics, Vol. 18, Suppl. I, pgs. 1-64 (February 1987).	
	58	Dworakowska and Dolowy, "Ion channels-related diseases," ACTA Biochimica Polonica, Vol. 47, No. 3, pgs. 685-703 (2000).	
	59	Escayg et al., "Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2," Nature Genetics, Vol. 24, pgs. 343-345 (April 2000).	
	60	European Patent Office Search Report corresponding to European Patent Application No. 07075566.5 - 2401 dated October 4, 2007.	
	61	Examiner's First Report for Australian Patent Application No. 2004200978 dated May 6, 2004.	
	62	Finkelstein et al., "Use of denaturing gradient gel electrophoresis for detection of mutation and prospective diagnosis in late onset ornithine transcarbamylase deficiency," Genomics, Vol. 7, pgs. 167-172 (1990).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	63	Fong et al., "Childhood Absence Epilepsy with Tonic-Clonic Seizures and Electroencephalogram 3–4-Hz Spike and Multispike–Slow Wave Complexes: Linkage to Chromosome 8q24," Am. J. Hum. Genet., Vol 63, pgs. 1117-1129 (1998).	
	64	Fujiwara et al., "Long-Term Course of Childhood Epilepsy with Intractable Grand Mal Seizures," Jpn. J. Psychiatry Neurol., Vol. 46, pgs. 297-302 (1992).	
	65	Fukuma G., "Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB)," Epilepsia, Vol. 45, No. 2, pgs. 140-148 (February 2004).	
	66	Gardiner, "Impact of our understanding of the genetic aetiology of epilepsy," J. Neurol., Vol. 247, pgs. 327-334 (2000).	
	67	Genbank accession number AB093548. 10/16/2002	
	68	Genbank accession number M22253. 10/26/1995	
	69	Genbank accession number NM_012647. 3/21/2010	
	70	Genbank Accession No. NM_172107. 8/5/2010	
	71	GenBank Locus AF225985, "Homo sapiens voltage-gated sodium channel alpha subunit SCN1A (SCN1A) mRNA, complete cds," pgs. 1-4 (Feb. 1, 2001).	
	72	GenBank Locus NM_006920, "Homo sapiens sodium channel, voltage-gated, type I, alpha (SCN1A), mRNA," pgs. 1-11 (Nov. 13, 2006).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	73	Gene Card for SCNA1 available via uri: <genecards.org/cgi-bin/carddisp.pl?gene=SCN1A> 11/16/2006	
	74	GeneCards output for protein-coding SCN1A, available online from www.genecards.org, pgs. 1-20. 7/23/07	
	75	Gennaro et al., "Familial severe myoclonic epilepsy of infancy: truncation of $Na_v1.1$ and genetic heterogeneity," Epileptic Disord., Vol. 5, pgs. 21-25 (2003).	
	76	Geysen H.M. et al., "Cognitive features of continuous antigenic determinants," Journal of Molecular Recognition, Vol. 1, pgs. 32-41 (1988).	
	77	Goldsby et al., "Immunology," Fifth Edition, section "Cross-Reactivity," pg. 141 (2003).	
	78	Greenberg et al., "Evidence for multiple gene loci in the expression of the common generalized epilepsies," Neurology, Vol. 42, Suppl. 5, pgs. 56-62 (April 1992).	
	79	Greenberg et al., "Juvenile Myoclonic Epilepsy (JME) May be Linked to the BF and HLA Loci on Human Chromosome 6," Am. J. of Medical Genetics, Vol. 31, pgs. 185-192 (1988).	
	80	Greenberg et al., "Segregation Analysis of Juvenile Myoclonic Epilepsy," Genetic Epidemiology, Vol. 5, pgs. 81-94 (1988).	
	81	Guerrini et al., "Lamotrigine and seizure aggravation in severe myoclonic epilepsy, Epilepsia, Vol. 39s, pgs. 508-512 (1998).	
	82	Harkin et al., "The Spectrum of SCN1A-Related Infantile Epileptic Encephalopathies," Brain, Vol. 130, pgs. 843-852 (2007).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 8 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	83	Hauser et al., "Incidence of Epilespy and Unprovoked Seizures in Rochester, Minnesota: 1935-1984," Epilepsia, Vol. 34, No. 3, pgs. 453-468 (1993).	
	84	Hille, "Ionic Channels of Exciteable Membranes," 2nd Edition, pgs. 423 and 434-444 (1992).	
	85	Hirschhorn et al., "A comprehensive review of genetic association studies," Genetics in Medicine, Vol. 4, No. 2, pgs. 45-61 (2002).	
	86	International Search Report for International Application No. PCT/AU2004/000295 dated May 14, 2004.	
	87	Interview Summary corresponding to U.S. Patent Application Serial No. 11/262,647 dated December 5, 2008.	
	88	Interview Summary corresponding to U.S. Patent Application Serial No. 10/806,899 dated November 23, 2009.	
	89	Interview Summary corresponding to U.S. Patent Application Serial No. 10/806,899 dated October 8, 2009.	
	90	Interview Summary corresponding to U.S. Patent Application Serial No. 10/806,899 dated November 1, 2007.	
	91	Janz et al., "Do idiopathic generalized epilepsies share a common susceptibility gene?" Neurology, Vol. 42, Suppl 5, pgs. 48-55 (April 1992).	
	92	Kanai et al., "Effect of localization of missense mutations in SCN1A on epilepsy phenotype severity," Neurology, Vol. 63, pgs. 329-334 (2004).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 9 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	93	Kimura K., "A missense mutation in SCN1A in brothers with severe myoclonic epilepsy in infancy (SMEI) inherited from a father with febrile seizures," Brain Dev., Vol. 27, No. 6, pgs. 424-430 (September 2005).	
	94	Kinzler et al., "Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers," Science, Vol. 251, pgs.1366-1370 (1991).	
	95	Kuhn et al., "Movement of voltage sensor S4 in domain 4 is tightly coupled to sodium channel fast inactivation and gating charge immobilization," J. Gen. Physiol., Vol. 114, pgs. 167-183 (1999).	
	96	Lason W., "Neurochemical and pharmacological aspects of cocaine-induced seizures," Polish Journal of Pharmacology, Vol. 53, pgs. 57-60 (2001).	
	97	Lerche et al., "Ion Channels and Epilepsy," Am. J. of Med. Genetics, Vol. 106, pgs. 146-159 (2001).	
	98	Lernmark and Ott, "Sometimes it's hot, sometimes it's not," Nature Genetics, Vol. 19, pgs. 213-214 (July 1998).	
	99	Lo et al., "High Level Expression and Secretion of Fc-X Fusion Proteins in Mammalian Cells," Protein Engineering, Vol. 11, pgs. 495-500 (1998).	
	100	Lopes-Cendes et al., "A New Locus for Generalized Epilepsy with Febrile Seizures Plus Maps to Chromosome 2," Am. J. Hum. Genet., Vol. 66, pgs. 698-701 (2000).	
	101	Lucentini, J., "Gene Asscoiation Studies Typically Wrong," The Scientist, pg. 20 (December 20, 2004).	
	102	Madia et al., "No evidence of GABRG2 mutations in severe myoclonic epilepsy of infancy," Epilepsy Research, Vol. 53, pgs. 196-200 (2003).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 10 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	103	Malacarne et al., "Lack of SCN1A Mutations in Familial Febrile Seizures," Epelepsia, Vol. 43, No. 5, pgs. 559-562 (2002).	
	104	Maxam et al., "A new method for sequencing DNA," Proceedings of the National Academy of Sciences of the USA, Vol. 74, No. 2, pgs. 560-564 (1977).	
	105	Mazumder et al., "Translations control by the 3'-UTR: the ends specify the means," Trends in Biochemical Sciences, Vol. 28, pgs. 91-98 (2004).	
	106	Modrich, Paul, "Mechanisms and biological effects of mismatch repair," Annual Review of Genetics, Vol. 25, pgs. 229-253 (1991).	
	107	Moran et al., "Skeletal Muscle Sodium Channel Is Affected by an Epileptogenic β1 Subunit Mutation," Biochem. Biophys. Res. Comm., Vol. 282, pgs. 55-59 (2001).	
	108	Moulard et al., "Identification of a New Locus for Generalized Epilepsy with Febrile Seizures Plus (GEFS+) on Chromosome 2q24-q33," Am. J. Hum. Genet., Vol. 65, pgs. 1396-1400 (1999).	
	109	Mulley et al., "SCN1A Mutations and Epilepsy," Human Mutation, Vol. 25, pgs. 535-542 (2005).	
	110	Mulley et al., "Channelopathies as a Genetic Cause of Epilepsy," Current Opinion in Neurology, Vol. 16, pgs. 171-176 (2003).	
	111	Notice of Allowance corresponding to U.S. Patent Application Serial No. 10/451,126 (Patent No. 7,078,515) dated August 30, 2005.	
	112	Notice of Allowance corresponding to U.S. Patent Application Serial No. 11/263,326 (Patent No. 7,282,336) dated June 18, 2007.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 11 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	113	Notice of Allowance corresponding to U.S. Patent Application Serial No. 11/262,647 dated December 18, 2009.	
	114	Notice of Allowance corresponding to U.S. Patent Application Serial No. 10/806,899 dated January 4, 2010.	
	115	Notification Concerning Transmittal of Copy of International Preliminary Report on Patentability for International Application No. PCT/AU2006/000841 dated January 3, 2008.	
	116	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated August 7, 2009.	
	117	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated December 30, 2008.	
	118	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated April 4, 2008.	
	119	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/482,834 dated August 2, 2007.	
	120	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated October 28, 2009.	
	121	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated May 13, 2009.	
	122	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated August 19, 2008.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 12 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	123	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated June 26, 2007.	
	124	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/806,899 dated November 29, 2006.	
	125	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/263,326 (Patent No. 7,282,336) dated October 6, 2006.	
	126	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/262,647 dated April 22, 2009.	
	127	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/262,647 dated December 5, 2008.	
	128	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 11/262,647 dated February 15, 2008.	
	129	Official Communication of U.S. Patent and Trademark Office corresponding to U.S. Patent Application Serial No. 10/451,126 (Patent No. 7,078,515) dated January 24, 2005.	
	130	Ohmori et al., "Significant correlation of the SCN1A mutations and severe myoclonic epilepsy in infancy," Biochemical and Biophysical Research Communications, Vol. 295, pgs. 17-23 (2002).	
	131	Ohtahara et al., "Lennox-Gastaut syndrome: a new vista," Psychiatry Clin. Neurosci., Vol. 49, pgs. S179-S183 (1995).	
	132	Ohtsuka et al., "Long-term prognosis of the Lennox-Gastaut syndrome," Jpn. J. Psychiatry Neurol., Vol. 44, pgs. 257-264 (1990).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 13 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	133	Ohtsuka et al., "Refractory Childhood Epilepsy and Factors Related to Refractoriness," Epilepsia, Vol. 41, Suppl. 9, pgs. 14-17 (2000).	
	134	Okubo et al., "Epileptiform EEG Discharges in Healthy Children: Prevalence, Emotional and Behavioral Correlates, and Genetic Influences," Epilepsia, Vol. 35, No. 4, pgs. 832-841 (1994).	
	135	Orita et al., "Detection of polymorphisms of human DNA by gel electrophoresis as single-strand confirmation polymorphisms," Proceedings of the National Academy of Sciences of the USA, Vol. 86, pgs. 2766-2770 (1989).	
	136	Panayiotopoulos and Obeid, "Juvenile Myoclonic Epilepsy: An Autosomal Recessive Disease," Ann Neurol, Vol. 25, pgs. 440-443 (1989).	
	137	Peiffer et al., "A Locus for Febrile Seizures (FEB3) Maps to Chromosome 2q23-24," Annals of Neurology, Vol. 46, No. 4, pgs. 671-678 (October 1999).	
	138	Phillips et al., "Autosomal Dominant Nocturnal Frontal-Lobe Epilepsy: Genetic Heterogeneity and Evidence for a Second Locus at 15q24," Am. J. Hum. Genet., Vol. 63, pgs. 1108-1116 (1998).	
	139	Phillips et al., "Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q13.2," Nature Genetics, Vol. 10, pgs.117-118 (May 1995).	
	140	Plummer et al., "Evolution and Diversity of Mammalian Sodium Channel Genes," Genomics, Vol. 57, pgs. 323-331 (1999).	
	141	Plummer et al.,"Exon Organization, Coding Sequence, Physical Mapping, and Polymorphic Intragenic Markers for the Human Neuronal Sodium Channel Gene SCN8A," Genomics, Vol. 54, pgs. 287-296 (1998).	
	142	Reutens and Berkovic, "Idiopathic generalized epilepsy of adolescence: Are the syndromes clinically distinct?" Neurology, Vol. 45, pgs. 1469-1476 (August 1995).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 14 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	143	Risch and Botstein, "A manic depressive history," Nature Genetics, Vol. 12, pgs. 351-353 (April 1996).	
	144	Sanger et al., "DNA sequencing with chain-terminating inhibitors," Proceedings of the National Academy of Sciences of the USA, Vol. 74, No. 12, pgs. 5463-5467 (1977).	
	145	Scheffer and Berkovic, "Generalized epilepsy with febrile seizures plus A genetic disorder with heterogeneous clinical phenotypes," Brain, Vol. 120, pgs. 479-490 (1997).	
	146	Scheffer et al., "Locus for Febrile Seizures," Annals of Neurology, Vol. 47, No. 6, pgs. 840-841 (June 2000).	
	147	Scheffer et al., "The Genetics of Human Epilepsy," TRENDS in Pharmacological Science, Vol. 24, No. 8, pgs. 428-433 (August 2003).	
	148	Sheffield et al., "Attachment of a 40-base-pair G+C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results," Proceedings of the National Academy of Sciences of the USA, Vol. 86, pgs. 232-236 (1989).	
	149	Singh et al., "A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns," Nature Genetics, Vol. 18, pgs. 25-29 (January 1998).	
	150	Singh et al., "Generalized Epilepsy with Febrile Seizures Plus: A Common Childhood-Onset Genetic Epilepsy Syndrome," Ann. Neurol., Vol. 45, pgs. 75-81 (1999).	
	151	Singh et al., "Severe Myoclonic Epilepsy of Infancy: Extended Spectrum of GEFS?" Epilepsia, Vol. 42, No. 7, pgs. 837-844 (2001).	
	152	Spampanato et al., "Generalized Epilepsy with Febrile Seizures Plus Type 2 Mutation W1204R Alters voltage-Dependent Gating of $Na_v1.1$ Sodium Channels," Neuroscience, Vol. 116, pgs. 37-48 (2003).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 15 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	153	Stafstrom et al., "Epilepsy Genes: The link between molecular dysfunction and pathophysiology", Mental Retardation and Developmental Disabilities Research Reviews, Vol. 6, pgs. 281-292 (2000).	
	154	Steinlein et al., "A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy," Nature Genetics, Vol. 11, pgs. 201-203 (October 1995).	
	155	Sugawara et al., "Frequent mutations of SCN1A in severe myoclonic epilepsy in infancy," Neurology, Vol. 58, pgs. 1122-1124 (2002).	
	156	Sugawara, T., "Nav1.1 channels with mutations of severe myoclonic epilepsy in infancy display attenuated currents," Epilepsy Res., Vol. 54, Nos. 2-3, pgs. 201-207 (May 2003).	
	157	Supplementary European Search Report corresponding to Australian Patent No. AU0200910 dated February 17, 2005.	
	158	Supplementary Partial European Search Report for Application No. 01271383.0-2406 dated March 12, 2004.	
	159	Taylor et al., "Enzymatic methods for mutation scanning," Genetic Analysis: Biomolecular Engineering, Vol. 14, pgs. 181-186 (1999).	
	160	Thisted, "What is a P-value?" available online from www.stat.uchicago.edu, pgs. 1-6 (May 25, 1998).	
	161	Todd, "Interpretation of results from genetic studies of multifactorial disease," Molecular Medicine, Vol. 354, pgs. 15-16 (July 1999).	
	162	Veggiotti et al., "Generalized Epilepsy with Febrile Seizures plus and Severe Myoclonic Epilepsy in Infancy: a case report of two Italian families," Epileptic Discord, Vol. 3, pgs. 29-32 (2001).	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.K./

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 16 of 16

Complete if Known	
Application Number	10/567,424
Filing Date	12/9/2008
First Named Inventor	Mulley et al.
Art Unit	1649
Examiner Name	Kolker, Daniel E.
Attorney Docket Number	1386/23

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	163	Wallace et al., "Febrile seizures and generalized epilepsy associated with a mutation in the Na^+-channel β1 subunit gene SCN1B," Nature Genetics, Vol. 19, pgs. 366-370 (August 1998).	
	164	Wallace et al., "Mutant $GABA_A$ receptor γ2-subunit in childhood absence epilepsy and febrile seizures," Nature Genetics, Vol. 28, pgs. 49-52 (May 2001).	
	165	Wallace et al., "Sodium Channel E L-Subunit Mutations in Severe Myoclonic Epilepsy of Infancy and Infantile Spasms," Neurology, Vol. 61, pgs. 765-769 (September 2003).	
	166	Wallace R., "A Plethora of SCN1A Mutations: What Can They Tell Us?" Epilepsy Curro., Vol. 5, No. 1, pgs. 17-20 (January 2005).	
	167	Wartell et al., "Detecting base pair substitutions in DNA fragments by temperature-gradient gel electrophoresis," Nucleic Acids Research, Vol. 18, No. 9, pgs. 2699-2705 (1990).	
	168	Zara et al., "Mapping of genes predisposing to idiopathic generalized epilepsy," Human Molecular Genetics, Vol. 4, No. 7, pgs. 1201-1207 (1995).	
	169	Zara et al., "Mapping of Locus for a Familial Autosomal Recessive Idiopathic Myoclonic Epilepsy of Infancy to Chromosome 16p13," Am. J. Hum. Genet., Vol. 66, pgs. 1552-1557 (2000).	

Examiner Signature	/Daniel Kolker/	Date Considered	02/09/2011

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.